The neuroprotective effect of GLP-1 analogs can alleviate the dyskinesia of the PD model, but it can also lead to constipation, abdominal pain, indigestion, anorexia, and other GI adverse reactions (Badawi et al., 2017). This evidence concerns the gene GCG and Parkinson disease.